Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on clinical characteristics: a meta-analysis

Area of Science:

• Immunotherapy
• Oncology
• Clinical Trials

Background:

• The combination of programmed cell death protein 1 (PD-1) or its ligand (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockade represents a promising strategy in cancer treatment.
• Understanding the relationship between dual blockade efficacy and patient clinical characteristics is crucial for personalized medicine.

Approach:

• A meta-analysis was conducted on 12 randomized clinical trials involving 7056 patients with solid tumors.
• The study evaluated the impact of dual PD-1/PD-L1 and CTLA-4 blockade compared to standard care on patient survival outcomes.

Key Points:

• Dual blockade therapy significantly improved overall survival (OS) and progression-free survival (PFS) compared to standard of care.
• Enhanced survival benefits were observed in specific patient subgroups: those younger than 75 years, individuals with a history of smoking, White patients, and those with a high tumor mutation burden.

Conclusions:

• Dual blockade of PD-1/PD-L1 and CTLA-4 demonstrates significant efficacy in improving survival outcomes for patients with solid tumors.
• Patient characteristics such as age, smoking history, race, and tumor mutation burden may serve as predictive biomarkers for response to dual blockade therapy.